Interleukin-10, Peroxisome proliferator-activated receptor gamma, Tumor necrosis factor alpha, and Interleukin-1 beta network (IL-10/PPARγ/TNF-α/IL-1β Network)

The Cytokine network involving Interleukin-10 (IL-10), Peroxisome proliferator-activated receptor gamma (PPARγ), Tumor necrosis factor alpha (TNF-α), and Interleukin-1 beta (IL-1β) represents a critical regulatory axis that maintains immune homeostasis. PPARγ is a nuclear receptor and transcription factor that exerts potent anti-inflammatory effects by transrepressing pro-inflammatory signaling pathways, such as NF-κB, which drive the expression of TNF-α and IL-1β (Ricote et al., Nature, 1998). Furthermore, PPARγ activation directly promotes the production of IL-10, an anti-inflammatory cytokine that provides feedback inhibition on the synthesis of pro-inflammatory mediators (Chung et al., J Biol Chem, 2000). In many chronic inflammatory and autoimmune diseases, this balance is disrupted, leading to a pathological state dominated by TNF-α and IL-1β (Tilg & Moschen, Nat Rev Immunol, 2006). Therapeutic strategies targeting this network include PPARγ agonists like thiazolidinediones, which are used in metabolic disorders but also show potential in inflammatory bowel disease, and biologics that neutralize TNF-α or IL-1β (Dinarello, N Engl J Med, 2009). However, modulating this network carries risks, including increased susceptibility to infections due to suppressed immune surveillance and specific side effects like fluid retention associated with PPARγ modulation (Nissen & Wolski, N Engl J Med, 2007). This network remains a focal point for understanding the transition from acute to chronic inflammation and for the development of precision immunotherapies.

Other names

PPARγ-cytokine axisInflammatory cytokine balanceIL-10/TNF-α ratio regulationAnti-inflammatory versus pro-inflammatory cytokine network

PPARγ agonists induce transrepression of pro-inflammatory genes (TNF, IL1B) and upregulate anti-inflammatory IL10; TNF-α and IL-1β inhibitors directly neutralize pro-inflammatory signaling.